# Nevia Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nevia-bio

- Industry: Healthcare IT
- Headquarters: Haifa, Israel
- Website: www.nevia.bio
- Total disclosed funding: $3M
- Latest round: Seed (Aug 29, 2023)
- Investors on record: 2

## About

Established in 2015 by Shlomit Yehudai-Reshef (CSO), and Inbal Zafir-Lavie (CEO), and based in Haifa, Israel, Nevia Bio Ltd., formerly known as Gina Life operates as a femtech company that develops a medical diagnostic platform for the early detection and prevention of ovarian cancer in women. In August 2023, Nevia Bio raised 1.9 million in pre-seed funding from various investors.



The firm develops a medical platform that employs artificial intelligence and machine learning (AI/ML) algorithms to detect cancer in an early stage based on sample data collected from the vaginal discharge of a large dataset of women. The platform compares test samples from the patient with the database to detect cancer or other diseases in the early stage to help prevent diseases like ovarian cancer, endometriosis, etc. 



The company intends to use the August 2023 funding to strengthen data science skills, expand its pipeline to further indications in the field of women's health, and assist with clinical studies for ovarian cancer.

## Funding rounds

- Seed, Aug 29, 2023, $3M — ALIVE, Technion - Israel Institute of Technology

## Investors

- ALIVE — Seed
- Technion - Israel Institute of Technology — Seed